StockData
Merck & Co., Inc. logo

Merck & Co., Inc.

MRKNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026Score 9/30242% above fair value
$148.36−1.16 (-0.78%)

Close on Nov 2, 2026Market cap $366.03BP/E 118.7Yield 2.21%

Merck Cubicin (daptomycin, legacy) — Worldwide sales by Quarter

Cubicin (daptomycin, legacy) — Worldwide sales ($M) ($M)

QuarterlyAnnual

Merck Cubicin (daptomycin, legacy) — Worldwide sales: $36M in Q4 2020, down 28.0% from a year earlier. No newer figure appears in the documents we track.

Latest, Q4 2020
36
Period ended Dec 31, 2020
Change on a year earlier
-28.0%
50 in Q4 2019
History
20 quarters
Since Q1 2016
Sources
4
Documents cited below

Where the Q4 2020 figure comes from

“|| Cubicin | 46 | 32 | 39 | 36 | 152 | 88 | 67 | 52 | 50 | 257 | -27 | -28 | -41 | -40”

Source: Form 8-K (tm213179d2_ex99-1.htm, filed 2021-02-04) ↗

Reported in Form 10-Q / 10-K Segment & Product Sales Footnote & Form 8-K Table 3 / 3a / 3b.

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedCubicin (daptomycin, legacy) — Worldwide sales ($M) ($M)Year on yearSource
Q4 2020Dec 31, 202036-28.0%Form 8-K (tm213179d2_ex99-1.htm, filed 2021-02-04) ↗
Q3 2020Sep 30, 202039-25.0%Form 8-K (tm213179d2_ex99-1.htm, filed 2021-02-04) ↗
Q2 2020Jun 30, 202032-52.2%Form 8-K (tm213179d2_ex99-1.htm, filed 2021-02-04) ↗
Q1 2020Mar 31, 202046-47.7%Form 8-K (tm213179d2_ex99-1.htm, filed 2021-02-04) ↗
Q4 2019Dec 31, 201950-37.5%Form 8-K (tm213179d2_ex99-1.htm, filed 2021-02-04) ↗
Q3 2019Sep 30, 201952-45.3%Form 8-K (tm213179d2_ex99-1.htm, filed 2021-02-04) ↗
Q2 2019Jun 30, 201967-28.7%Form 8-K (tm213179d2_ex99-1.htm, filed 2021-02-04) ↗
Q1 2019Mar 31, 201988-10.2%Form 8-K (tm213179d2_ex99-1.htm, filed 2021-02-04) ↗
Q4 2018Dec 31, 201880-13.0%Form 8-K (tm206551d1_ex99-1.htm, filed 2020-02-05) ↗
Q3 2018Sep 30, 201895+4.4%Form 8-K (tm206551d1_ex99-1.htm, filed 2020-02-05) ↗
Q2 2018Jun 30, 201894-8.7%Form 8-K (tm206551d1_ex99-1.htm, filed 2020-02-05) ↗
Q1 2018Mar 31, 201898+2.1%Form 8-K (tm206551d1_ex99-1.htm, filed 2020-02-05) ↗
Q4 2017Dec 31, 201792-22.7%Form 8-K (a19-3795_1ex99d1.htm, filed 2019-02-01) ↗
Q3 2017Sep 30, 201791-71.6%Form 8-K (a19-3795_1ex99d1.htm, filed 2019-02-01) ↗
Q2 2017Jun 30, 2017103-71.1%Form 8-K (a19-3795_1ex99d1.htm, filed 2019-02-01) ↗
Q1 2017Mar 31, 201796-67.1%Form 8-K (a19-3795_1ex99d1.htm, filed 2019-02-01) ↗

Breakdown

What makes up cubicin (daptomycin, legacy) — Worldwide sales

Cite this data

StockData. (2026). Merck Cubicin (daptomycin, legacy) — Worldwide sales ($M), quarterly Q1 2016–Q4 2020 [Data set]. Compiled from Merck SEC filings and investor materials. https://stockdatahq.com/stocks/mrk/kpis/rev-cubicin

See every metric in the Merck KPI table. Data updated Oct 26, 2026.